{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T07:34:01Z","timestamp":1791185641523,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,11,5]],"date-time":"2013-11-05T00:00:00Z","timestamp":1383609600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1186\/1471-2407-13-523","type":"journal-article","created":{"date-parts":[[2013,11,5]],"date-time":"2013-11-05T12:03:04Z","timestamp":1383652984000},"source":"Crossref","is-referenced-by-count":50,"title":["BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer"],"prefix":"10.1186","volume":"13","author":[{"given":"William","family":"Jacot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Thezenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Senal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Viglianti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Claire","family":"Laberenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyne","family":"Lopez-Crapez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Bibeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Bleuse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Romieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Jean","family":"Lamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,11,5]]},"reference":[{"issue":"2","key":"4151_CR1","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ab.2008.07.007","volume":"381","author":"X Liu","year":"2008","unstructured":"Liu X, Palma J, Kinders R, Shi Y, Donawho C, Ellis PA, Rodriguez LE, Colon-Lopez M, Saltarelli M, LeBlond D, et al: An enzyme-linked immunosorbent poly(ADP-ribose) polymerase biomarker assay for clinical trials of PARP inhibitors. Anal Biochem. 2008, 381 (2): 240-247. 10.1016\/j.ab.2008.07.007.","journal-title":"Anal Biochem"},{"issue":"3","key":"4151_CR2","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/nrc2342","volume":"8","author":"T Helleday","year":"2008","unstructured":"Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA: DNA repair pathways as targets for cancer therapy. Nat Rev Cancer. 2008, 8 (3): 193-204.","journal-title":"Nat Rev Cancer"},{"issue":"9737","key":"4151_CR3","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S0140-6736(10)60892-6","volume":"376","author":"A Tutt","year":"2010","unstructured":"Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK, et al: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010, 376 (9737): 235-244. 10.1016\/S0140-6736(10)60892-6.","journal-title":"Lancet"},{"issue":"23","key":"4151_CR4","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1056\/NEJMra012284","volume":"348","author":"R Wooster","year":"2003","unstructured":"Wooster R, Weber BL: Breast and ovarian cancer. N Engl J Med. 2003, 348 (23): 2339-2347. 10.1056\/NEJMra012284.","journal-title":"N Engl J Med"},{"issue":"Pt 2","key":"4151_CR5","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1042\/bj3420249","volume":"342","author":"D D\u2019Amours","year":"1999","unstructured":"D\u2019Amours D, Desnoyers S, D\u2019Silva I, Poirier GG: Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J. 1999, 342 (Pt 2): 249-268.","journal-title":"Biochem J"},{"issue":"7","key":"4151_CR6","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nrm1963","volume":"7","author":"V Schreiber","year":"2006","unstructured":"Schreiber V, Dantzer F, Ame JC, de Murcia G: Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol. 2006, 7 (7): 517-528. 10.1038\/nrm1963.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"8","key":"4151_CR7","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1002\/bies.20085","volume":"26","author":"JC Ame","year":"2004","unstructured":"Ame JC, Spenlehauer C, de Murcia G: The PARP superfamily. Bioessays. 2004, 26 (8): 882-893. 10.1002\/bies.20085.","journal-title":"Bioessays"},{"issue":"7035","key":"4151_CR8","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T: Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005, 434 (7035): 913-917. 10.1038\/nature03443.","journal-title":"Nature"},{"issue":"7035","key":"4151_CR9","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, et al: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005, 434 (7035): 917-921. 10.1038\/nature03445.","journal-title":"Nature"},{"issue":"4","key":"4151_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S146239940500904X","volume":"7","author":"NJ Curtin","year":"2005","unstructured":"Curtin NJ: PARP inhibitors for cancer therapy. Expert Rev Mol Med. 2005, 7 (4): 1-20.","journal-title":"Expert Rev Mol Med"},{"issue":"6","key":"4151_CR11","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1517\/14728222.11.6.783","volume":"11","author":"N Curtin","year":"2007","unstructured":"Curtin N: Therapeutic potential of drugs to modulate DNA repair in cancer. Expert Opin Ther Targets. 2007, 11 (6): 783-799. 10.1517\/14728222.11.6.783.","journal-title":"Expert Opin Ther Targets"},{"issue":"3","key":"4151_CR12","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s10549-011-1441-2","volume":"127","author":"P Domagala","year":"2011","unstructured":"Domagala P, Huzarski T, Lubinski J, Gugala K, Domagala W: PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy. Breast Cancer Res Treat. 2011, 127 (3): 861-869. 10.1007\/s10549-011-1441-2.","journal-title":"Breast Cancer Res Treat"},{"issue":"16","key":"4151_CR13","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1200\/JCO.2010.31.9079","volume":"29","author":"G von Minckwitz","year":"2011","unstructured":"von Minckwitz G, Muller BM, Loibl S, Budczies J, Hanusch C, Darb-Esfahani S, Hilfrich J, Weiss E, Huober J, Blohmer JU, et al: Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol. 2011, 29 (16): 2150-2157. 10.1200\/JCO.2010.31.9079.","journal-title":"J Clin Oncol"},{"issue":"5","key":"4151_CR14","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1093\/annonc\/mdr361","volume":"23","author":"F Rojo","year":"2012","unstructured":"Rojo F, Garcia-Parra J, Zazo S, Tusquets I, Ferrer-Lozano J, Menendez S, Eroles P, Chamizo C, Servitja S, Ramirez-Merino N, et al: Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer. Ann Oncol. 2012, 23 (5): 1156-1164. 10.1093\/annonc\/mdr361.","journal-title":"Ann Oncol"},{"issue":"18","key":"4151_CR15","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1093\/jnci\/djp315","volume":"101","author":"RS Tuma","year":"2009","unstructured":"Tuma RS: PARP inhibitors: will the new class of drugs match the hype?. J Natl Cancer Inst. 2009, 101 (18): 1230-1232. 10.1093\/jnci\/djp315.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"4151_CR16","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1200\/JCO.1998.16.5.1969","volume":"16","author":"MA Blackwood","year":"1998","unstructured":"Blackwood MA, Weber BL: BRCA1 and BRCA2: from molecular genetics to clinical medicine. J Clin Oncol. 1998, 16 (5): 1969-1977.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4151_CR17","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/ng0696-245","volume":"13","author":"Y Miki","year":"1996","unstructured":"Miki Y, Katagiri T, Kasumi F, Yoshimoto T, Nakamura Y: Mutation analysis in the BRCA2 gene in primary breast cancers. Nat Genet. 1996, 13 (2): 245-247. 10.1038\/ng0696-245.","journal-title":"Nat Genet"},{"issue":"5182","key":"4151_CR18","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1126\/science.7545954","volume":"266","author":"Y Miki","year":"1994","unstructured":"Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, et al: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994, 266 (5182): 66-71. 10.1126\/science.7545954.","journal-title":"Science"},{"issue":"3","key":"4151_CR19","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00428-012-1286-z","volume":"461","author":"A Bal","year":"2012","unstructured":"Bal A, Verma S, Joshi K, Singla A, Thakur R, Arora S, Singh G: BRCA1-methylated sporadic breast cancers are BRCA-like in showing a basal phenotype and absence of ER expression. Virchows Arch. 2012, 461 (3): 305-312. 10.1007\/s00428-012-1286-z.","journal-title":"Virchows Arch"},{"issue":"4","key":"4151_CR20","doi-asserted-by":"publisher","first-page":"R38","DOI":"10.1186\/bcr1522","volume":"8","author":"V Birgisdottir","year":"2006","unstructured":"Birgisdottir V, Stefansson OA, Bodvarsdottir SK, Hilmarsdottir H, Jonasson JG, Eyfjord JE: Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res. 2006, 8 (4): R38-10.1186\/bcr1522.","journal-title":"Breast Cancer Res"},{"issue":"4","key":"4151_CR21","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1093\/annonc\/mdq468","volume":"22","author":"EH Lips","year":"2011","unstructured":"Lips EH, Mulder L, Hannemann J, Laddach N, Vrancken Peeters MT, van de Vijver MJ, Wesseling J, Nederlof PM, Rodenhuis S: Indicators of homologous recombination deficiency in breast cancer and association with response to neoadjuvant chemotherapy. Ann Oncol. 2011, 22 (4): 870-876. 10.1093\/annonc\/mdq468.","journal-title":"Ann Oncol"},{"issue":"4","key":"4151_CR22","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.lfs.2007.05.012","volume":"81","author":"S Mirza","year":"2007","unstructured":"Mirza S, Sharma G, Prasad CP, Parshad R, Srivastava A, Gupta SD, Ralhan R: Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients. Life Sci. 2007, 81 (4): 280-287. 10.1016\/j.lfs.2007.05.012.","journal-title":"Life Sci"},{"issue":"23","key":"4151_CR23","doi-asserted-by":"publisher","first-page":"10692","DOI":"10.1158\/0008-5472.CAN-05-1277","volume":"65","author":"M Wei","year":"2005","unstructured":"Wei M, Grushko TA, Dignam J, Hagos F, Nanda R, Sveen L, Xu J, Fackenthal J, Tretiakova M, Das S, et al: BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. Cancer Res. 2005, 65 (23): 10692-10699. 10.1158\/0008-5472.CAN-05-1277.","journal-title":"Cancer Res"},{"issue":"10","key":"4151_CR24","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1038\/bjc.2013.144","volume":"108","author":"EH Lips","year":"2013","unstructured":"Lips EH, Mulder L, Oonk A, van der Kolk LE, Hogervorst FB, Imholz AL, Wesseling J, Rodenhuis S, Nederlof PM: Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers. Br J Cancer. 2013, 108 (10): 2172-2177. 10.1038\/bjc.2013.144.","journal-title":"Br J Cancer"},{"issue":"4","key":"4151_CR25","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1158\/2159-8290.CD-11-0206","volume":"2","author":"NJ Birkbak","year":"2012","unstructured":"Birkbak NJ, Wang ZC, Kim JY, Eklund AC, Li Q, Tian R, Bowman-Colin C, Li Y, Greene-Colozzi A, Iglehart JD, et al: Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents. Cancer Discov. 2012, 2 (4): 366-375. 10.1158\/2159-8290.CD-11-0206.","journal-title":"Cancer Discov"},{"issue":"5597","key":"4151_CR26","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1126\/science.1076182","volume":"298","author":"B Wang","year":"2002","unstructured":"Wang B, Matsuoka S, Carpenter PB, Elledge SJ: 53BP1, a mediator of the DNA damage checkpoint. Science. 2002, 298 (5597): 1435-1438. 10.1126\/science.1076182.","journal-title":"Science"},{"issue":"50","key":"4151_CR27","doi-asserted-by":"publisher","first-page":"38472","DOI":"10.1074\/jbc.M607577200","volume":"281","author":"I Ward","year":"2006","unstructured":"Ward I, Kim JE, Minn K, Chini CC, Mer G, Chen J: The tandem BRCT domain of 53BP1 is not required for its repair function. J Biol Chem. 2006, 281 (50): 38472-38477. 10.1074\/jbc.M607577200.","journal-title":"J Biol Chem"},{"issue":"Pt 4","key":"4151_CR28","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1042\/BST0370897","volume":"37","author":"JE FitzGerald","year":"2009","unstructured":"FitzGerald JE, Grenon M, Lowndes NF: 53BP1: function and mechanisms of focal recruitment. Biochem Soc Trans. 2009, 37 (Pt 4): 897-904.","journal-title":"Biochem Soc Trans"},{"issue":"3","key":"4151_CR29","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.mehy.2011.05.015","volume":"77","author":"Q Huo","year":"2011","unstructured":"Huo Q, Yang Q: P53-binding protein 1: a new player for tumorigenesis and a new target for breast cancer treatment. Med Hypotheses. 2011, 77 (3): 359-363. 10.1016\/j.mehy.2011.05.015.","journal-title":"Med Hypotheses"},{"issue":"6","key":"4151_CR30","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1038\/nsmb.1831","volume":"17","author":"P Bouwman","year":"2010","unstructured":"Bouwman P, Aly A, Escandell JM, Pieterse M, Bartkova J, van der Gulden H, Hiddingh S, Thanasoula M, Kulkarni A, Yang Q, et al: 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol. 2010, 17 (6): 688-695. 10.1038\/nsmb.1831.","journal-title":"Nat Struct Mol Biol"},{"issue":"2","key":"4151_CR31","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.cell.2010.03.012","volume":"141","author":"SF Bunting","year":"2010","unstructured":"Bunting SF, Callen E, Wong N, Chen HT, Polato F, Gunn A, Bothmer A, Feldhahn N, Fernandez-Capetillo O, Cao L, et al: 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell. 2010, 141 (2): 243-254. 10.1016\/j.cell.2010.03.012.","journal-title":"Cell"},{"issue":"1","key":"4151_CR32","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1093\/jmcb\/mjq055","volume":"3","author":"A Aly","year":"2011","unstructured":"Aly A, Ganesan S: BRCA1, PARP, and 53BP1: conditional synthetic lethality and synthetic viability. J Mol Cell Biol. 2011, 3 (1): 66-74. 10.1093\/jmcb\/mjq055.","journal-title":"J Mol Cell Biol"},{"issue":"1","key":"4151_CR33","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1158\/2159-8290.CD-12-0049","volume":"3","author":"JE Jaspers","year":"2013","unstructured":"Jaspers JE, Kersbergen A, Boon U, Sol W, van Deemter L, Zander SA, Drost R, Wientjens E, Ji J, Aly A, et al: Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov. 2013, 3 (1): 68-81. 10.1158\/2159-8290.CD-12-0049.","journal-title":"Cancer Discov"},{"issue":"9","key":"4151_CR34","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","volume":"12","author":"KA Gelmon","year":"2011","unstructured":"Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, et al: Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011, 12 (9): 852-861. 10.1016\/S1470-2045(11)70214-5.","journal-title":"Lancet Oncol"},{"issue":"4","key":"4151_CR35","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1093\/jnci\/djq509","volume":"103","author":"Y Drew","year":"2011","unstructured":"Drew Y, Mulligan EA, Vong WT, Thomas HD, Kahn S, Kyle S, Mukhopadhyay A, Los G, Hostomsky Z, Plummer ER, et al: Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J Natl Cancer Inst. 2011, 103 (4): 334-346. 10.1093\/jnci\/djq509.","journal-title":"J Natl Cancer Inst"},{"issue":"29","key":"4151_CR36","doi-asserted-by":"publisher","first-page":"e563","DOI":"10.1200\/JCO.2010.30.1010","volume":"28","author":"J Veeck","year":"2010","unstructured":"Veeck J, Ropero S, Setien F, Gonzalez-Suarez E, Osorio A, Benitez J, Herman JG, Esteller M: BRCA1 CpG island hypermethylation predicts sensitivity to poly(adenosine diphosphate)-ribose polymerase inhibitors. J Clin Oncol. 2010, 28 (29): e563-564. 10.1200\/JCO.2010.30.1010. author reply e565-566","journal-title":"J Clin Oncol"},{"issue":"3","key":"4151_CR37","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1309\/K4JAF2NMD5EJU67Y","volume":"128","author":"PJ Lamy","year":"2007","unstructured":"Lamy PJ, Verjat T, Servanton AC, Paye M, Leissner P, Mougin B: Urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 mRNA assessment in breast cancer by means of NASBA: correlation with protein expression. Am J Clin Pathol. 2007, 128 (3): 404-413. 10.1309\/K4JAF2NMD5EJU67Y.","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"4151_CR38","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/j.1365-2559.1991.tb00229.x","volume":"19","author":"CW Elston","year":"1991","unstructured":"Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991, 19 (5): 403-410. 10.1111\/j.1365-2559.1991.tb00229.x.","journal-title":"Histopathology"},{"issue":"1","key":"4151_CR39","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/sj.bjc.6605462","volume":"102","author":"S Mallett","year":"2010","unstructured":"Mallett S, Timmer A, Sauerbrei W, Altman DG: Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines. Br J Cancer. 2010, 102 (1): 173-180. 10.1038\/sj.bjc.6605462.","journal-title":"Br J Cancer"},{"issue":"7","key":"4151_CR40","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/jnci\/92.7.564","volume":"92","author":"M Esteller","year":"2000","unstructured":"Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, Bussaglia E, Prat J, Harkes IC, Repasky EA, et al: Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst. 2000, 92 (7): 564-569. 10.1093\/jnci\/92.7.564.","journal-title":"J Natl Cancer Inst"},{"issue":"34","key":"4151_CR41","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.1200\/JCO.2011.38.1988","volume":"29","author":"L Ozretic","year":"2011","unstructured":"Ozretic L, Rhiem K, Huss S, Wappenschmidt B, Markiefka B, Sinn P, Schmutzler RK, Buettner R: High nuclear poly(adenosine diphosphate-ribose) polymerase expression is predictive for BRCA1- and BRCA2-deficient breast cancer. J Clin Oncol. 2011, 29 (34): 4586-4588. 10.1200\/JCO.2011.38.1988.","journal-title":"J Clin Oncol"},{"issue":"6","key":"4151_CR42","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/j.1365-2559.2006.02402.x","volume":"48","author":"P Jalava","year":"2006","unstructured":"Jalava P, Kuopio T, Juntti-Patinen L, Kotkansalo T, Kronqvist P, Collan Y: Ki67 immunohistochemistry: a valuable marker in prognostication but with a risk of misclassification: proliferation subgroups formed based on Ki67 immunoreactivity and standardized mitotic index. Histopathology. 2006, 48 (6): 674-682. 10.1111\/j.1365-2559.2006.02402.x.","journal-title":"Histopathology"},{"issue":"1","key":"4151_CR43","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s10549-007-9766-6","volume":"111","author":"M Wei","year":"2008","unstructured":"Wei M, Xu J, Dignam J, Nanda R, Sveen L, Fackenthal J, Grushko TA, Olopade OI: Estrogen receptor alpha, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers. Breast Cancer Res Treat. 2008, 111 (1): 113-120. 10.1007\/s10549-007-9766-6.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"4151_CR44","doi-asserted-by":"publisher","first-page":"85","DOI":"10.4149\/neo_2012_011","volume":"59","author":"ME Krasteva","year":"2012","unstructured":"Krasteva ME, Bozhanov SS, Antov GG, Gospodinova ZI, Angelov SG: Breast cancer patients with hypermethylation in the promoter of BRCA1 gene exhibit favorable clinical status. Neoplasma. 2012, 59 (1): 85-91. 10.4149\/neo_2012_011.","journal-title":"Neoplasma"},{"issue":"10","key":"4151_CR45","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1093\/annonc\/mdi326","volume":"16","author":"A Goldhirsch","year":"2005","unstructured":"Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ, Panel M: Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol. 2005, 16 (10): 1569-1583. 10.1093\/annonc\/mdi326.","journal-title":"Ann Oncol"},{"key":"4151_CR46","volume-title":"American Society of Clinical Oncology: June 3\u20137, 2011","author":"JS O\u2019Shaughnessy","year":"2011","unstructured":"O\u2019Shaughnessy JS, Schwartzberg L, Danso MA, Rugo HS, Miller K, Yardley DA, Carlson RW, Finn RS, Charpentier E, Freese M: A Randomized Phase III Study of Iniparib (BSI-201) in Combination with Gemcitabine\/Carboplatin (G\/C) in Metastatic Triple-Negative Breast Cancer (TNBC). American Society of Clinical Oncology: June 3\u20137, 2011. 2011, Chicago, Illinois: J Clin Oncol, 2011: Abstract 1007"},{"issue":"6","key":"4151_CR47","doi-asserted-by":"publisher","first-page":"E2176","DOI":"10.1002\/humu.21478","volume":"32","author":"H Hellebrand","year":"2011","unstructured":"Hellebrand H, Sutter C, Honisch E, Gross E, Wappenschmidt B, Schem C, Deissler H, Ditsch N, Gress V, Kiechle M, et al: Germline mutations in the PALB2 gene are population specific and occur with low frequencies in familial breast cancer. Hum Mutat. 2011, 32 (6): E2176-2188. 10.1002\/humu.21478.","journal-title":"Hum Mutat"},{"issue":"3","key":"4151_CR48","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1515\/cclm-2011-0840","volume":"50","author":"N Poumpouridou","year":"2012","unstructured":"Poumpouridou N, Kroupis C: Hereditary breast cancer: beyond BRCA genetic analysis; PALB2 emerges. Clin Chem Lab Med. 2012, 50 (3): 423-434.","journal-title":"Clin Chem Lab Med"},{"issue":"10","key":"4151_CR49","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1038\/nsmb.1915","volume":"17","author":"R Buisson","year":"2010","unstructured":"Buisson R, Dion-Cote AM, Coulombe Y, Launay H, Cai H, Stasiak AZ, Stasiak A, Xia B, Masson JY: Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination. Nat Struct Mol Biol. 2010, 17 (10): 1247-1254. 10.1038\/nsmb.1915.","journal-title":"Nat Struct Mol Biol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-13-523.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-13-523\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-13-523","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T01:26:07Z","timestamp":1498094767000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-13-523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,5]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["4151"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-13-523","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,5]]},"article-number":"523"}}